For those of you who have Fosamax – femur fracture lawsuits filed on your behalf or have been monitoring this particular set of drug injury cases, I want to let you know at the outset that the take-away message from this latest update from Merck is either “more of the same” or “not much has changed”.
In Merck & Co., Inc.’s corporate report Form 10-Q for the first quarter of 2016 — which was released on or about May 5, 2016 — we get this information about the thousands of Fosamax – femur fracture cases filed against the drug company:
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Fosamax (Fosamax Litigation)…. [P]laintiffs in approximately 4,405 of these actions generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax….
As of March 31, 2016, approximately 20 cases were pending in the Femur Fracture MDL, excluding the 515 cases dismissed with prejudice on preemption grounds that are pending appeal and the 520 cases dismissed without prejudice that are also pending the aforementioned appeal.
As of March 31, 2016, approximately 3,040 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge Jessica Mayer in Middlesex County….
As of March 31, 2016, approximately 300 cases alleging Femur Fractures have been filed and are pending in California state court. A petition was filed seeking to coordinate all Femur Fracture cases filed in California state court before a single judge in Orange County, California…. The next Femur Fracture trial in California that was scheduled to begin on April 25, 2016, was stayed at plaintiffs’ request and a new trial date has not been set.
Be assured that we will continue to watch for any significant developments as regards these Fosamax – femur fracture lawsuits in 2016 and report such events out to you.[Read this article in full at original source]